abelheira schreef op 16 maart 2020 11:53:
Met dank aan @Paniekvogel.
Onderstaand antwoord ontving ik zojuist op mijn vraag aan GLPG m.b.t. de impact:
Hieronder het antwoord dat we vorige week deelden met onze analisten.
Hopelijk helpt dit. Dit zijn zeker moeilijke dagen voor alle bedrijven, inclusief in onze sector, maar we hopen dat de boodschap hieronder duidelijk maakt dat we een sterk business continuity plan hebben.
Vriendelijke groeten, en dank voor uw vertrouwen,
We’ve had a few questions come in on our preparedness for the corona virus:
In light of the COVID-19 outbreak, Galapagos has strong measures in place to help prevent spread of the virus and protect the health of our staff, while ensuring business continuity.
Such measures include limiting non-essential travel, canceling all travel to high-risk areas, asking people in high-risk areas to work from home where possible, and reminding everyone of good hygiene practices. Our global and site business continuity plans, and appropriate recommended travel precautions and restrictions, are active and up to date.
Our security practices are designed with both known and unknown risks in mind. Access to our facilities is highly secure and requires careful scheduling, compliance with entrance procedures, wearing the appropriate personal protective equipment, and following disinfection and sanitization practices. We also have specific visitor policies at our sites in order to minimize risk of exposure and business disruption.
We have a business continuity plan for our non-clinical and clinical trials, including a pandemic response plan. This entails all parameters of the study including efficacy, safety, PK/PD, and drug supply, in order to ensure adequate guidance is provided to sites and mitigation measures are in place. To date, patient visits in our clinical trials have continued with minimal impact.
Build-up of our commercial operations in the EU5 countries to prepare for potential launch continues well. Gilead’s IR stands ready to address any questions or concerns around manufacturing of filgotinib.
As we continue to monitor the situation closely, we are confident that our procedures are robust and that our employees and facilities are sound and secure. At present, there is no impact on trial timelines. Our business continuity is successfully ensuring our routine site-based operations, as well as clinical trial operations, are sustained.